Alvotech and Cipla Medpro, a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as "Cipla"), have entered into an exclusive partnership to bring key biosimilars to patients in emerging markets such as South Africa.

Alvotech announced today that its parent company, Alvotech Holdings SA, has successfully completed a $65 million private placement round. This has resulted in the company issuing new shares to a group of new investors and existing shareholders, which will further finance the development and release

Alvotech and DKSH, a leading healthcare provider across 36 emerging countries in South-East Asia, today announced an expansion of their strategic partnership to commercialize six new biosimilar product candidates for the Asian markets. The initial pipeline contains biosimilar candidates addressing

Alvotech and Teva bring together highly complementary capabilities to secure a leading position in the U.S. biosimilar market The collaboration is one of the broadest partnerships within the U.S. biosimilar industry to date to accelerate improved patient access for high quality biosimilar medicines

Alvotech is developing AVT02 as a proposed biosimilar to HUMIRA® (adalimumab) with high concentration (100mg/mL) dosage forms The Phase 1 PK similarity study for AVT02 (AVT02-GL-101) has met its primary objectives The Phase 3 confirmatory efficacy and safety study for AVT02 (AVT02-GL-301) has met

Alvotech Hf and DKSH, a leading healthcare provider across 36 emerging countries in South-East Asia, today announced that Alvotech Hf and DKSH have entered into an exclusive license partnership for the commercialization of AVT02, an adalimumab biosimilar, in selected APAC markets.

Alvotech and JAMP Pharma have entered into an agreement for an exclusive partnership to supply and commercialize five leading biosimilar candidates in the Canadian market. The current market value of the branded sales for these biosimilars is estimated to exceed $2 billion annually.

ALVOTECH and STADA enter into a strategic collaboration for seven biosimilar candidates in Europe STADA will exclusively commercialize the products in all key European markets as well as selected markets outside of Europe STADA CEO Peter Goldschmidt: “The agreement with Alvotech is one of the

Alvotech and Cipla Gulf FZ LLC (“Cipla Gulf”), a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as "Cipla"), today announced that Alvotech and Cipla Gulf have entered into an exclusive partnership for the

Alvotech AVT02 is developed as a high concentration (100mg/mL) formulation, expected to be more convenient for patients, differentiating from most biosimilar competitors 407 participants enrolled in the Phase III study, at approximately 30 sites across Europe Simultaneous Phase I PK comparability